TC-SP 14
TC-SP 14 (compound 14) is an orally active and potent S1P1 agonist (EC50 = 0.042 μM) with minimal activity at S1P3 (EC50 = 3.47 μM). TC-SP 14 significantly reduces blood lymphocyte counts and attenuates a delayed type hypersensitivity (DTH) response to antigen challenge.
For research use only. We do not sell to patients.
- CAS No.: 1257093-40-5
- Formula: C25H20F2N2O2S
- Molecular Weight:450.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-108496
Sphingosine-1-phosphateS1PR Agonist -
HY-101395
W146S1PR1 Antagonist -
HY-100675
JTE-013S1P2 Antagonist -
HY-108491
N,N-DimethylsphingosineSphingosine Kinase Inhibitor -
HY-W008947
SEW2871S1P1 Agonist -
HY-101419
CYM-5541S1P3 Receptor Agonist -
HY-10968
CYM5442S1P1 Receptor Agonist -
HY-108490
VPC 23019S1P1/3 Antagonist -
HY-100953
CYM-5520S1PR2 Agonist -
HY-108494
CYM50260S1P4 Receptor Agonist -
HY-12835
S1P1 agonist IIIS1P1 Agonist -
HY-12005
Fingolimod hydrochlorideS1P Receptors Modulator
Biological Activity
Description
IC50 & Target
|
S1PR1 0.042 μM (EC50) |
S1PR3 3.47 μM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
3.47 μM
Compound: 14
|
Agonist activity at human S1P3 receptor expressed in CHO-K1 cells co-expressing Gq/i5 G-protein assessed as calcium mobilization by FLIPR assay
Agonist activity at human S1P3 receptor expressed in CHO-K1 cells co-expressing Gq/i5 G-protein assessed as calcium mobilization by FLIPR assay
|
[PMID: 24900287] |
| U2OS | EC50 |
0.042 μM
Compound: 14
|
Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization after 1 hr
Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization after 1 hr
|
[PMID: 24900287] |
In Vitro
TC-SP 14 (compound 14) neither inhibits nor induces human cytochrome P450 enzymes, is nonmutagenic, and dose not significantly inhibit the hERG channel[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
TC-SP 14 (0-3 mg/kg, Orally, daily for 10 days) significant reduces ovalbumin (OVA)-induced ear swelling[1].
TC-SP 14 (2-15 mg/kg, IV or PO, once) possesses acceptable characteristics[1].
Pharmacokinetic Parameters of TC-SP 14 in female Sprague-Dawley rats and male Cynomolgus [1].
| species | rat | NHP |
| CL (L/h/kg) | 0.33 | 0.50 |
| Vss (L/kg) | 3.3 | 1.6 |
| T1/2 (h) | 7.5 | 35.2 |
| MRT (h) | 10 | 3.3 |
| % F | 68 | 23 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (female, n = 5/group)[1]
-
Dosage:0.3, 1.0, and 3.0 mg/kg
-
Administration:Orally, once
-
Result:Produced a dose-dependent reduction in circulating blood lymphocytes 24 h postdose, resulted in near maximal lymphopenia at 3.0 mg/kg (74% reduction in lymphocytes vs vehicle).
-
Animal Model:OVA-immunized Lewis rats (female, n = 8/group)[1]
-
Dosage:0.1, 0.3, 1.0, and 3.0 mg/kg
-
Administration:Orally, daily for 10 days
-
Result:Significant reduced OVA-induced ear swelling at doses of 0.3 mg/kg and higher.
-
Animal Model:Female Sprague-Dawley rats, Male Cynomolgus (NHP (nonhuman primates)) (n=3/group)[1]
-
Dosage:2 (IV, rat), 4 (IV, NHP), 10 (PO, NHP), 15 mg/kg (PO, rat)
-
Administration:IV, PO, once (Pharmacokinetic Analysis)
-
Result:Possessed acceptable characteristics, demonstrated low clearance, moderate steady state volumes of distribution, moderate-to-long mean residence times, and acceptable oral bioavailability.
Chemical Information
-
CAS No. 1257093-40-5
-
Molecular Weight 450.50
-
Formula C25H20F2N2O2S
-
SMILES
O=C(C1CN(CC2=CC=C(C3=NC4=CC(CC5=CC=CC=C5F)=CC=C4S3)C(F)=C2)C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Contact Hypersensitivity Dermatitis
Contact hypersensitivity (CHS) dermatitis is a T cell-mediated delayed-type (Type IV) immune reaction in which low-molecular-weight haptens applied to the skin bind host proteins to form complete antigens, triggering sensitization followed by a secondary inflammatory response upon re-exposure (elicitation phase), which is commonly quantified by ear swelling as a readout of skin inflammation in murine models. This model is widely used to study allergic contact dermatitis because it is antigen-specific, reproducible, and reflects key immunological events including dendritic cell activation, T cell priming in draining lymph nodes, and effector T cell-driven tissue inflammation. DNFB- and oxazolone-induced CHS models are standard systems for evaluating both acute and chronic T cell-dependent skin inflammation and for testing immunomodulatory interventions.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TC-SP 14 Related Classifications
HY-108492 Related Classifications
Powered by Bioz